Visfatin/PBEF/Nampt: A new cardiovascular target?

Frontiers in Pharmacology

Volumn 1 NOV, Issue , 2010, Pages

  Peiró, Concepción ^a   Romacho, Tania ^a   Carraro, Raffaele ^a,b   Sánchez Ferrer, Carlos F ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Adipocytokine; Atherosclerosis; Inflammation; Proliferation; visfatin PBEF Nampt

Indexed keywords

EID: 84865840226     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2010.00135     Document Type: Article

References (52)

1. Adya, R., Tan, B. K., Punn, A., Chen, J., and Randeva, H. S. (2008a). Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 78, 356-365.
2. Adya, R., Tan, B. K., Chen, J., and Randeva, H. S. (2008b). Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 31, 758-760.
3. Adya, R., Tan, B. K., Chen, J., and Randeva, H. S. (2009). Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 205, 113-119.
4. Arner, P. (2006). Visfatin-a true or false trail to type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 91, 28-30.
5. Bae, Y. H., Bae, M. K., Kim, S. R., Lee, J. H., Wee, H. J., and Bae, S. K. (2009). Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochem. Biophys. Res. Commun. 379, 206-211.
6. Bi, T. Q., and Che, X. M. (2010). Nampt/PBEF/visfatin and cancer. Cancer Biol. Ther. 10, 119-125.
7. Dahl, T. B., Yndestad, A., Skjelland, M., Øie, E., Dahl, A., Michelsen, A., Damås, J. K., Tunheim, S. H., Ueland, T., Smith, C., Bendz, B., Tonstad, S., Gullestad, L., Frøland, S. S., Krohg-Sørensen, K., Russell, D., Aukrust, P., and Halvorsen, B. (2007). Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115, 972-980.
8. Fiedler, L. R., Bachetti, T., Leiper, J., Zachary, I., Chen, L., Renné, T., and Wojciak-Stothard, B. (2009). The ADMA/DDAH pathway regulates VEGF-mediated angiogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 2117-2124.
9. Filippatos, T. D., Randeva, H. S., Derdemezis, C. S., Elisaf, M. S., and Mikhailidis, D. P. (2010). Visfatin/PBEF and atherosclerosis-related diseases. Curr. Vasc. Pharmacol. 8, 12-28.
10. Formentini, L., Moroni, F., and Chiarugi, A. (2009). Detection andpharmacological modulation of nicotinamide mononucleotide (NMN) in vitroand in vivo. Biochem. Pharmacol. 77, 1612-1620.
11. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., Watanabe, E., Takagi, T., Akiyoshi, M., Ohtsubo, T., Kihara, S., Yamashita, S., Makishima, M., Funahashi, T., Yamanaka, S., Hiramatsu, R., Matsuzawa, Y., and Shimomura, I. (2005). Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307, 426-430.
12. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., Watanabe, E., Takagi, T., Akiyoshi, M., Ohtsubo, T., Kihara, S., Yamashita, S., Makishima, M., Funahashi, T., Yamanaka, S., Hiramatsu, R., Matsuzawa, Y., and Shimomura, I. (2007). Retraction. Science 318, 565.
13. Galkina, E., and Ley, K. (2007). Vascular adhesion molecules in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27, 2292-2301.
14. Garten, A., Petzold, S., Körner, A., Imai, S., and Kiess, W. (2009). Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 20, 130-138.
15. Guzik, T. J., Mangalat, D., and Korbut, R. (2006). Adipocytokines. Novel link between inflammation and vascular function? J. Physiol. Pharmacol. 57, 505-528.
16. Hausenloy, D. J., and Yellon, D. M. (2003). The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J. Mol. Cell Cardiol. 35, 339-341.
17. Ho, C., van der Veer, E., Akawi, O., and Pickering, J. G. (2009). Sirt1 markedly extends replicative lifespan if the nad+ salvage pathway is enhanced. FEBS Lett. 583, 3081-3085.
18. Kadoglou, N. P., Sailer, N., Moumtzouoglou, A., Kapelouzou, A., Tsanikidis, H., Vitta, I., Karkos, C., Karayannacos, P. E., Gerasimidis, T., and Liapis, C. D. (2010). Visfatin (NAMPT) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 118, 75-80.
19. Karastergiou, K., and Mohamed-Ali, V. (2010). The autocrine and paracrine roles of adipokines. Mol. Cell Endocrinol. 318, 69-78.
20. Kato, A., Odamaki, M., Ishida, J., and Hishida, A. (2009). Relationship between serum pre-b cellcolony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am. J. Nephrol. 29, 31-35.
21. Kim, J. Y., Bae, Y. H., Bae, M. K., Kim, S. R., Park, H. J., Wee, H. J., and Bae, S. K. (2009). Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim. Biophys. Acta 1793, 1759-1767.
22. Kim, S. R., Bae, Y. H., Bae, S. K., Choi, K. S., Yoon, K. H., Koo, T. H., Jang, H. O., Yun, I., Kim, K. W., Kwon, Y. G., Yoo, M. A., and Bae, M. K. (2008). Visfatin enhances ICAM-1 and VCAM-1 expression through ros-dependent NF-kappaB activation in endothelial cells. Biochim. Biophys. Acta 1783, 886-895.
23. Kim, S. R., Bae, S. K., Choi, K. S., Park, S. Y., Jun, H. O., Lee, J. Y., Jang, H. O., Yun, I., Yoon, K. H., Kim, Y. J., Yoo, M. A., Kim, K. W., and Bae, M. K. (2007). Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem. Biophys. Res. Commun. 357, 150-156.
24. Lau, D. C., Dhillon, B., Yan, H., Szmitko, P. E., and Verma, S. (2005). Adipokines: molecular links between obesity and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 288, 2031-2041.
25. Lee, W. J., Wu, C. S., Lin, H., Lee, I. T., Wu, C. M., Tseng, J. J., Chou, M. M., and Sheu, W. H. (2009). Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-?B pathway. Int. J. Obes. (Lond). 33, 465-472.
26. Li, Y., Zhang, Y., Dorweiler, B., Cui, D., Wang, T., Woo, C. W., Brunkan, C. S., Wolberger, C., Imai, S., and Tabas, I. (2008). Extracellular nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 283, 34833-34843.
27. Lim, S. Y., Davidson, S. M., Paramanathan, A. J., Smith, C. C., Yellon, D. M., and Hausenloy, D. J. (2008). The novel adipocytokine visfatin exerts direct cardioprotective effects. J. Cell Mol. Med. 12, 1395-1403.
28. Liu, S. W., Qiao, S. B., Yuan, J. S., and Liu, D. Q. (2009a). Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin. Endocrinol. (Oxf). 71, 202-207.
29. Liu, S. W., Qiao, S. B., Yuan, J. S., and Liu, D. Q. (2009b). Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in humanvein umbilical endothelial cells. Horm. Metab. Res. 41, 281-286.
30. Lovren, F., Pan, Y., Shukla, P. C., Quan, A., Teoh, H., Szmitko, P. E., Peterson, M. D., Gupta, M., Al-Omran, M., and Verma, S. (2009). Visfatin activates eNOS via Akt and MAP Kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am. J. Physiol. Endocrinol. Metab. 296, 1440-1449.
31. Moschen, A. R., Gerner, R. R., and Tilg, H. (2010). Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr. Pharm. Des. 16, 1913-1920.
32. Oki, K., Yamane, K., Kamei, N., Nojima, H., and Kohno, N. (2007). Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin. Endocrinol. (Oxf). 67, 796-800.
33. Pacher, P., Obrosova, I. G., Mabley, J. G., and Szabo, C. (2005). Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr. Med. Chem. 12, 267-275.
34. Pogrebniak, A., Schemainda, I., Azzam, K., Pelka-Fleischer, R., Nüssler, V., and Hasmann, M. (2006). Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur. J. Med. Res. 11, 313-321.
35. Ravaud, A., Cerny, T., Terret, C., Wanders, J., Bui, B. N., Hess, D., Droz, J. P., Fumoleau, P., and Twelves, C. (2005). Phase I study and pharmakokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur. J. Cancer 41, 702-707.
36. Revollo, J. R., Grimm, A. A., and Imai, S. (2004). The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279, 50754-50763.
37. Revollo, J. R., Körner, A., Mills, K. F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R. R., Milbrandt, J., Kiess, W., and Imai, S. (2007). Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6, 363-375.
38. Romacho, T., Azcutia, V., Vázquez-Bella, M., Matesanz, N., Cercas, E., Nevado, J., Carraro, R., Rodríguez-Mañas, L., Sánchez-Ferrer, C. F., and Peiró, C. (2009). Extracellular PBEF/NAMPT/visfatin activates pro-inflammatorysignalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52, 2455-2463.
39. Rongvaux, A., Shea, R. J., Mulks, M. H., Gigot, D., Urbain, J., Leo, O., and Andris, F. (2002). Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32, 3225-3234.
40. Samal, B., Sun, Y., Stearns, G., Xie, C., Suggs, S., and McNiece, I. (1994). Cloning and characterization of the cdna encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell Biol. 14, 1431-1437.
41. Sandeep, S., Velmurugan, K., Deepa, R., and Mohan, V. (2007). Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56, 565-570.
42. Spiroglou, S. G., Kostopoulos, C. G., Varakis, J. N., and Papadaki, H. H. (2010). Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J. Atheroscler. Thromb. 17, 115-130.
43. Stephens, J. M., and Vidal-Puig, A. J. (2006). An update on visfatin/pre-b cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr. Opin. Lipidol. 17, 128-131.
44. Takebayashi, K., Suetsugu, M., Wakabayashi, S., Aso, Y., and Inukai, T. (2007). Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56, 451-458.
45. van der Veer, E., Ho, C., O'Neil, C., Barbosa, N., Scott, R., Cregan, S. P., and Pickering, J. G. (2007). Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J. Biol. Chem. 282, 10841-10845.
46. van der Veer, E., Nong, Z., O'Neil, C., Urquhart, B., Freeman, D., and Pickering, J. G. (2005). Pre-b-cell colony-enhancing factor regulates NAD + -dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ. Res. 97, 25-34.
47. Wang, P., Xu, T. Y., Guan, Y. F., Su, D. F., Fan, G. R., and Miao, C. Y. (2009). Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc. Res. 81, 370-380.
48. Xiao, J., Xiao, Z. J., Liu, Z. G., Gong, H. Y., Yuan, Q., Wang, S., Li, Y. J., and Jiang, D. J. (2009). Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells. Diabetes Metab. Res. Rev. 25, 242-249.
49. Yamawaki, H., Hara, N., Okada, M., and Hara, Y. (2009). Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem. Biophys. Res. Commun. 383, 503-508.
50. Yilmaz, M. I., Saglam, M., Carrero, J. J., Qureshi, A. R., Caglar, K., Eyileten, T., Sonmez, A., Cakir, E., Yenicesu, M., Lindholm, B., Stenvinkel, P., and Axelsson, J. (2008). Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol. Dial. Transplant. 23, 959-965.
51. Yilmaz, M. I., Saglam, M., Carrero, J. J., Qureshi, A. R., Caglar, K., Eyileten, T., Sonmez, A., Oguz, Y., Aslan, I., Vural, A., Yenicesu, M., Stenvinkel, P., Lindholm, B., and Axelsson, J. (2009). Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/nampt. A novel marker of endothelial damage? Clin. Transplant. 23, 241-248.
52. Yu, X. Y., Qiao, S. B., Guan, H. S., Liu, S. W., and Meng, X. M. (2010). Effects of visfatin on proliferation and collagen synthesis in rat cardiac fibroblasts. Horm. Metab. Res. 42, 507-513.